ГОРМОНАЛЬНАЯ ТЕРАПИЯ С ИСПОЛЬЗОВАНИЕМ АГОНИСТОВ И АНТАГОНИСТОВ ЛЮТЕИНИЗИ- РУЮЩЕГО ГОРМОНА РЕЛИЗИНГ ГОРМОНА У БОЛЬНЫХ РАКОМ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ

Рак предстательной железы (РПЖ) является одной из наиболее актуальных проблем современной онкоурологии. Гормональная терапия (ГТ) с использованием медикаментозной кастрации является основным методом лечения больных метастатическим РПЖ. ГТ с использованием нового класса препаратов, блокирующих рецепторы лютеинизирующего гормона релизинг гормона (ЛГРГ), является перспективным и эффективным методом кастрационной терапии, обладающим рядом существенных преимуществ по сравнению с использованием аналогов ЛГРГ. В статье представлен обзор результатов исследований, сравнивших эффективность и побочные эффекты ГТ с использованием антагонистов и аналогов ЛГРГ.

1. Sostojanie onkologicheskoj pomoshhi naseleniju Rossii v 2012 godu [Kniga]//Pod red. A. D. Kaprina V. V. Starinskogo, G. V. Petrovoj. – M: FGBU «MNIOI im. P. A. Gercena» Minzdrava Rossii, 2013. – str. 128.

2. Huggins C, Hoges C. V. Studies on prostate cancer. The effect of castration [Journal]//Cancer Res. – 1941. – pp. 385–402.

3. Malkowicz S. B. The role of diethylstilbestrol in the treatment of prostate cancer [Journal]//Urology. – 2001. – Vol. 58. – pp. 108–13.

4. Alekseev B.Ja., Njushko K. M. Gormonal’naja terapija bol’nyh rakom predstatel’noj zhelezy [Zhurnal]//Onkourologija. – 2007 g. – T. 3. – str. 57–62.

5. Kaisary A. V., Tyrrell C. J., Peeling W. B. et al. Comparison of LHRH analogue with orchiectomy in patients with metastatic prostatic carcinoma [Journal]//Br J Urol. – 1991. – Vol. 67. – pp. 502–8.

6. Rusakov I. G., Alekseev B.Ja., Njushko K. M. Gormonal’naja terapija preparatom lejprorelin (ljukrin-depo®) u bol’nyh rakom predstatel’noj zhelezy [Zhurnal]//Onkourologija. – 2009 g. – T. 3. – str. 56–60.

7. Alekseev B.Ja., Njushko K. M., Vorob’ev N. V. i dr. Chastota i lokalizacija metastazov v limfaticheskih uzlah pri vypolnenii radikal’noj prostatjektomii i rasshirennoj tazovoj limfadenjektomii u bol’nyh rakom predstatel’noj zhelezy [Zhurnal]//Onkourologija. – 2012 g. – T. 1. – str. 77–82.

8. Alekseev B.Ja., Njushko K. M. Rasshirennaja tazovaja limfadenjektomija pri hirurgicheskom lechenii raka predstatel’noj zhelezy [Zhurnal]//Vrach. – 2010 g. – T. 11. – str. 63–64.

9. Alekseev B.Ja., Njushko K. M. Ad#juvantnaja gormonal’naja terapija kak metod radikal’nogo lechenija u bol’nyh mestno-rasprostranennym rakom predstatel’noj zhelezy [Zhurnal]//Onkourologija. – 2007 g. – T. 2. – str. 61–63.

10. Alekseev B.Ja., Njushko K. M. Radikal’naja prostatjektomija s rasshirennoj tazovoj limfadenjektomiej i ad#juvantnaja gormonal’naja terapija u bol’nyh limfogenno-disseminirovannym rakom predstatel’noj zhelezy [Zhurnal]//Onkourologija. – 2011 g. – T. 3. – str. 118–121.

11. Keating N. L., O’Malley A. J., Freedland S. J. et al. Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer [Journal]// J Natl Cancer Inst. – 2010. – Vol. 102. – pp. 39–46.

12. Bubley G. J. Is the flare phenomenon clinically significant? [Journal]//Urology. – 2001. – Vol. 58. – pp. 5–9.

13. Bertaglia V., Tucci M., Fiori C. et al. Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer [Journal]//Clin Genitourin Cancer. – 2013. – Vol. 11. – pp. 325–330.

14. Rick F. G., Block N. L., Schally A. V. An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer [Journal]//Onco Targets Ther. – 2013. – Vol. 16. – pp. 391–402.

15. Anderson J. Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer [Journal]//Future Oncol. – 2009. – Vol. 5. – pp. 433–43.

16. Persson B. E., Kold Olesen T., Jensen J. K. Degarelix: a new approach for the treatment of prostate cancer [Journal]//Neuroendocrinology. – 2009. – Vol. 90. – pp. 235–44.

17. Klotz L., Boccon-Gibod L., Shore N. D. et al. The efficacy and safety of degarelix: a 12‑month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. [Journal]//BJU Int. – 2008. – Vol. 102. – pp. 1531–8.

18. Crawford E. D., Shore N. D., Moul J. W. et al. Long-term tolerability and efficacy of degarelix: 5‑year results from a phase III extension trial with a 1‑arm crossover from leuprolide to degarelix [Journal]//Urology. – 2014. – Vol. 83. – pp. 1122–8.

19. Klotz L., Miller K., Crawford E. D. et al. Disease Control Outcomes from Analysis of Pooled Individual Patient Data from Five Comparative Randomised Clinical Trials of Degarelix Versus Luteinising Hormone-releasing Hormone Agonists [Journal]//Eur Urol. – 2014. – Vol. 66. – pp. 1101–8.

20. Kurt Miller, Christoph Rüssel, Sandra Goble et al. Open-label, exploratory study of degarelix as second-line hormonal therapy in patients with prostate cancer (CS27)//Poster 678. – [s. l.]: EAU, 2013.

21. Van Poppel H1, Klotz L. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists [Journal]//Int J Urol. – 2012. – Vol. 19. – pp. 594–601.

22. Smith M. R.1, Klotz L., van der Meulen E. et al. Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix [Journal]//J Urol. – 2011. – Vol. 186. – pp. 1835–42.

23. Tanriverdi F., Gonzalez-Martinez D., Hu Y. et al. GnRH-I and GnRHII have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin‑2 receptor gamma-chain mRNA expression in healthy males [Journal]//Clin Exp Immunol. – 2005. – Vol. 142. – pp. 103–10.

24. Chen H. F., Jeung E. B., Stephenson M., Leung P. C. Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin‑2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro [Journal]//J Clin Endocrinol Metab. – 1999. – Vol. 84. – pp. 743–50.